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ABSTRACT 
 
Leptin is a hormone influencing food intake, energy expenditure and body weight. It is pro-
duced by adipocytes, exerts its effects on brain, endocrine pancreas and other organs by acti-
vating trans-membrane receptors and is cleared from plasma mainly by the kidneys. Several 
studies have suggested that leptin's effects on metabolism are mediated by the liver. Our aim 
was to evaluate the role of the liver in the metabolism of leptin by comparing the serum leptin 
level in the portal vein with that in inferior vena cava and to study the relationship between 
leptin and lipoprotein levels in healthy and nephrotic rats. Experimental nephrotic syndrome 
was conducted in rats by intraperitoneal injection of the supernatant from the kidney suspen-
sion obtained by previous unilateral nephrectomy of the same rat and complete Freund's adju-
vant. There was a highly significant rise in leptin and lipid profile levels in the nephrotic rats 
compared with the normal rats. A highly significant increase in leptin in the inferior vena cava 
was detected compared with the level in the portal veins of nephrotic rats, while insignificant 
difference was observed in normal rats. This work has stressed the role of liver in leptin and 
lipid metabolism in nephrotic rats. 
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INTRODUCTION 
Leptin is a hormone influencing food 
intake, energy expenditure and body 
weight. This hormone is produced by adi-
pocytes, exerts its effects on brain, endo-
crine pancreas and other organs by activat-
ing trans-membrane receptors and is cleared 
from plasma mainly by the kidneys 
(Chabova et al., 1999). The kidney plays a 
key role in the systemic elimination of cir-
culating leptin (Cumin et al., 1997). Huang 
et al. (2006) established a role for leptin in 
the acute regulation of liver triglyceride 
(TG) levels in vivo. Leptin-induced de-
creases in triglyceride secretion from the 
liver also suggest a role for leptin in deter-
mining the triglyceride content of very low-
density lipoprotein (VLDL), a critical de-
terminant of the plasma lipoprotein profile. 
The mechanisms responsible for decreased 
intrahepatic triglyceride stores and triglyc-
eride secretion probably involve nutrient 
partitioning away from storage, because 
leptin increases the activity of fat oxidation 
pathways in liver. Several studies have sug-
gested that leptin's effects on metabolism 
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are mediated by the liver. This possibility 
has been suggested based on the liver's in-
tegral role in lipid metabolism and its sig-
nificant energetic demands of approximate-
ly 20 % of standard metabolic rate (SMR) 
in the rat (Porter and Brand, 1993). and lep-
tin's ability to suppress stearoyl-CoA de-
saturase 1 (SCD-1) in liver (Cohen et al., 
2002). And  leptin's reduction of the oxida-
tion system in liver mitochondria of ob/ob 
mice could either be a result of normalizing 
leptin levels or secondary to its ability to 
correct hepatic steatosis (Singh et al., 
2009). Singh et al. (2009) suggested that the 
reduced substrate oxidation and marked in-
crease in VLDL secretion by the liver seen 
after leptin treatment suggest that the hor-
mone causes the liver to reduce its own 
metabolic activity and shunt lipids to other 
tissues where they are metabolized. If, as 
the data suggest the liver is a conduit for 
nutrients that are metabolized elsewhere, 
where then these exported hepatic lipid 
stores being oxidized. The results showed 
that leptin treatment decreases coupled res-
piration in both skeletal muscle and the 
heart, thus causing a decrease in the replica-
tion-competent retrovirus (RCR) of these 
tissues. Thus the mechanism by which lep-
tin increases energy expenditure is not clear 
and could include effects on mitochondrial 
coupling as well as non-mitochondrial res-
piration, such as metabolic futile cycles in 
heart and muscle and/or effects in other tis-
sues, such as white adipose tissue (Wang et 
al., 1999). Leptin mediates hepatic stellate 
cells (HSC) activation and liver fibrosis 
through indirect effects on Kupffer cells 
(KC); these effects are partly mediated by 
TGF-beta1 (Wang et al., 2009). The liver 
has an integral role in lipid metabolism and 
also has significant energetic demands; 
therefore, studies have suggested that lep-
tin's effect on metabolism may be mediated 
by the liver. Leptin-deficient mice have 
significant abnormalities in macronutrient 
metabolism, which can be corrected by lep-
tin administration. A recent study has 
shown that acute leptin infusion rapidly re-
verses hepatic steatosis and plasma 
dyslipidemia induced by a high sucrose diet 
in rats, and the preservation of hepatic lep-
tin action after a high sucrose diet is associ-
ated with the maintenance of low adiposity 
and plasma leptin concentrations (Sharma 
et al., 2010; Huang et al., 2007). 
Nephrotic syndrome remains a serious 
clinical condition characterized by marked 
proteinurea, hypoproteinemia and hyper-
cholesterolemia, usually accompanied by 
the presence of oedema. It could be pre-
sumed that leptin plays an important role in 
the complex metabolic processes occurring 
in patients with nephrotic syndrome (Merta 
et al., 2003). In children with nephrotic 
kidney, urinary leptin excretion is increased 
but its level is unchanged in serum; serum 
leptin level correlated with lipid parameters 
(Wasilewska et al., 2005). Serum leptin 
levels were slightly increased in the active 
phase of the nephrotic syndrome (Ece et al., 
2004). Nicola et al. (1996) demonstrated 
that the nephrotic kidney might participate 
in the de novo synthesis or interconversion 
of the lipoproteins were higher in the active 
phase of the nephrotic syndrome (Ece et al., 
2004).  
The nephrotic liver secretes more lipo-
proteins than the normal liver: It secreted 
twice as much VLDL and HDL2 and 30 % 
more LDL and HDL1 than the normal liver; 
this was accompanied by an increased se-
cretion of both apolipoprotein A-I and apo-
lipoprotein E (Vaziri and Liang, 2004). 
Apolipoprotein A-I is persistently found in 
LDL of nephrotic rats but not in LDL of the 
controls, in HDL1 of nephrotic rats 
apolipoprotein A-I replaces apolipoprotein 
E as the major constituent peptide and the 
relative content of apolipoprotein A-I in 
HDL2 of nephrotic rats is enhanced (Vaziri 
and Liang, 2004; Calandra et al., 1981; 
Gherardi and Calandra, 1980). 
The aim of the present work was to 
evaluate the role of the liver in the metabo-
lism of leptin by comparing the serum lep-
tin level in the portal vein with that of the 
inferior vena cava and to study the relation-
ship between leptin and lipoprotein levels 
in healthy and nephrotic rats. 
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MATERIALS AND METHODS 
Experimental animals: Thirty male albi-
no rats weighed 160-190 gm, from the An-
imal House of the National Research Cen-
tre, were used. Rats were fed on a stock diet 
composed of whole wheat meal, skimmed 
milk powder, fish flour, dry yeast, stabi-
lized vitamin A, D and NDP energy of 12 
% (Morcos, 1980). Diet was given in plenty 
to the rats throughout the experimentation 
period (for 3 months). Animals were pro-
vided with water ad-libitum. The animal 
experiments were done in accordance with 
the regulations of the Ethical Committee of 
the National Research Centre.  
The rats were divided into two equal 
groups (each group consisted of 15 rats):  
Group I: saline-treated group served as 
healthy controls.  
Group II: had their kidneys made ne-
phrotic by injecting them intraperitoneally 
with 0.2 cc low speed supernatant (3000-
4000 rpm for 1-1.5 hours) of 1:2 blood free 
own kidney in saline obtained by previous 
unilateral nephrectomy with 0.3 Freund’s 
complete adjuvant (is an antigen emulsified 
in mineral oil, used to stimulate production 
of tumour necrosis factor). Each rat was 
injected six whole injections one each 14 
days) after the technique of Heymann et al. 
(1959). 
 
Unilateral nephrectomy 
General anaesthesia of rats was done 
through inhalation of Di-ethyl ether, the 
hair at the site of operation was clipped and 
shaved then washed by soap and water, and 
disinfected by alcohol 70 %, followed by 
Tincture iodine 4 %. A longtidunal incision 
in the skin and muscles was made, and by 
blunt forceps the wound was widened till 
appearance of the kidney. Strong ligation to 
the renal artery and renal vein was made 
separately followed by excision of kidney. 
After nephrectomy, coaptation of the 
wound occurred by lemberet’s sutures. In-
traperitoneal injections of operated rats had 
been done after complete recovery for 
about four weeks. 
Biochemical analysis 
Blood samples were obtained from the 
portal vein and inferior vena cava under 
ether anaesthesia. Blood was collected by 
using syringe into dry clean test tubes, then 
allowed to clot and centrifuged at 4000 rpm 
for 10 minutes to separate the serum. Serum 
was collected into dry clean test tubes and 
low density lipoprotein (LDL-Cholesterol) 
was determined immediately. The rest of 
serum was frozen at -20 °C for the subse-
quent estimation of the other parameters. 
 
Estimation of serum leptin  
Leptin was estimated by an immunoen-
zymometric assay for the quantitative 
measurement of human leptin in serum and 
plasma “The Biosource Leptin Enzyme 
Amplified Sensitivity Immuno assay (EAS-
IA)”. The kit was supplied by BioSource 
Europe S.A., rue de l’ Industrie 8, B-1400 
Nivelles, Belgium. 
 
Determination of serum total cholesterol 
Total cholesterol was determined using 
the enzymatic method of Allain et al., 
(1974). Using the total cholesterol kit of 
Bio-Merieux Laboratory Reagents and 
Products. Bio-Merieux 69280 Marcy-1, 
Etoile, France. 
 
Determination of serum triglycerides 
Serum triglyceride was determined by 
the quantitative enzymatic calorimetric de-
termination of triglycerides according to 
Wahlefeld (1974) by using Stanbio Enzy-
matic 2930 East Houston street, San Anto-
nio, Texas 78202 USA. 
 
Determination of serum phospholipids  
Serum phospholipid was determined by 
enzymatic method according to Trinder 
(1969) using phospholipids kit of Quimica 
Clinica Aplicada 43870 Amposta/Tarra-
gona, Espana. HDL-cholesterol was esti-
mated according to Glatter equation (1984) 
where 
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Serum HDL-Cholesterol =  
Total cholesterol 
5
deTriglyceri  + LDL-cholesterol 
 
Determination of serum LDL-cholesterol  
Serum LDL-cholesterol was determined 
according to Steinberg (1981) by using 
LDL cholesterol/phospholipids kit of Bio 
Merieux Laboratory Reagents and Products 
Bio Merieux 69280 Marcy-1, Etoile, France  
 
Determination of serum VLDL-cholesterol  
VLDL-cholesterol was estimated ac-
cording to Glatter equation (1984). 
 
Determination of serum apolipoprotein A-
1 and B (Apo A-1, B) 
Apolipoprotein A-1 and B were esti-
mated by immunoprecipitin analysis meth-
od according to Finley et al. (1976). Apo A-
1 kits obtained from Atlantic Antibodies, 
An INCSTAR Company INCSTAR Corpo-
ration-Stillwater, Minnesota, U.S.A.  
 
Statistical analysis of data  
Data are expressed as mean ± S.E. Sta-
tistical significance of the difference was 
analyzed using one way-ANOVA and post-
hoc Duncan test for multiple group compar-
ison. P values of <0.05 were considered sta-
tistically significant. The correlation coeffi-
cient (r) which is a measure of the degree of 
closeness of the linear relationship between 
two variables (X and Y) was determined, r 
always lies between -1 and +1 . 
 
RESULTS 
There was a nonsignificant rise in lep-
tin, apolipoprotein A-I and apolipoprotein 
B levels in the inferior vena cava compared 
with the portal venous blood of normal rats. 
However, a significant rise in leptin, 
apolipoprotein A-I and apolipoprotein B 
was detected in the inferior vena cava com-
pared with its level in the portal venous 
blood of nephrotic rats (Table 1). Also there 
was a high serum leptin, apolipoprotein A-I 
and apolipoprotein B levels in the nephrotic 
rats compared with the normal controls 
(Table 1). There was an insignificant 
change in lipid profile in the inferior vena 
cava compared with the portal venous 
blood of normal rats (Table 2) and a signif-
icant rise in lipid profile in the inferior vena 
cava compared with its level in the portal 
venous blood of nephrotic rats (Table 2). 
There was high serum all lipid profile levels 
in the nephrotic rats compared with the 
normal controls (Table 2). There was no 
correlation between portal venous serum 
leptin and serum lipids in normal control as 
in nephrotic rats except for triglycerides 
and HDL (+ve) and apolipoprotein A-1 and 
apolipoprotein B (-ve). Also there was no 
correlation between portal venous serum 
leptin and serum lipids in nephrotic rats ex-
cept for apolipoprotein A-1 and apolipopro-
tein B (-ve) (Tables 3, 4). There was no cor-
relation between inferior vena cava serum 
leptin and serum lipids in normal control 
and nephrotic rats except for apolipoprotein 
A-1 (-ve) (Tables 3, 4). 
 
Table 1: Serum leptin, apolipoprotein A-1 and 
apolipoprotein B levels in portal vein and inferi-
or vena cava blood in different experimental 
groups 
Group Leptin Apolipo-
protein 
A-1 
Apolipo-
protein B 
portal 
vein – 
Control  
(n=9) 
2.36±0.04 
 
47.02±0.43 
 
34.34±0.41 
 
inferior 
vena cava 
– Control  
(n=9) 
2.4±0.045 
 
46.54±0.31 
 
33.93±0.38 
 
portal vein 
– Nephrotic 
(n=9) 
3.53*±0.048 
 
104.58*±0.33 
 
85.15*±0.37 
 
inferior 
vena cava 
– Nephrotic 
(n=9) 
3.69**+±0.054 
 
114.13**+±0.27 
 
93.15**+±0.95 
 
Statistical differences were observed between:  
p < 0.05: portal vein – Control and portal vein – 
Nephrotic* 
p < 0.05: inferior vena cava – Control and infe-
rior vena cava – Nephrotic ** 
p < 0.05: portal vein – Nephrotic and inferior 
vena cava – Nephrotic+ 
n: number of rats/groups 
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Table 2: Serum lipid fractions in portal vein and inferior vena cava blood in different experimental 
groups 
Group Total  
cholesterol 
Triglycerides Phospholipids Low density 
lipoproteins 
High density 
lipoproteins 
Very low den-
sity  
lipoproteins 
portal vein –
Control  
n=9  
77.54±1.87 66.72±1.51 
 
131.12±2.25 
 
27.52±1.56 
 
36.68±0.85 
 
13.35±0.3 
 
inferior vena 
cava –  
Control  
n=9 
76.79±1.77 
 
64.82±1.52 
 
129.81±2.07 
 
27.94±1.89 
 
35.73±1.04 
 
12.97±0.3 
 
portal vein – 
Nephrotic 
n=8  
129.47*±.36 
 
185.74*±1.48 
 
205.94*±1.1 
 
34.92*±1.11 
 
57.39*±0.13 
 
37.15*±0.3 
 
inferior vena 
cava – Ne-
phrotic 
n=8 
156.08**+±1.48 235.37**+±2.17 
 
244.55**+±2.53 
 
34.59**±1.13 
 
74.49**+±0.48 
 
46.99**+±0.46 
 
 
Statistical differences were observed between:  
p < 0.05: portal vein – Control and portal vein – Nephrotic* 
p < 0.05: inferior vena cava – Control and inferior vena cava – Nephrotic ** 
p < 0.05:  portal vein – Nephrotic and inferior vena cava – Nephrotic+ 
n: number of rats/groups 
 
Table 3: Correlation between leptin and serum lipid profile in portal vein of normal control and ne-
phrotic rats 
NS = Not significant 
 
 
Table 4: Correlation between leptin and serum lipids in inferior vena cava of normal control and ne-
phrotic rats 
NS = Not significant 
Group  Total cho-
lesterol 
Trigly 
cerides 
Phospho-
lipids 
Low 
density 
lipo-
proteins 
High 
density  
lipo-
proteins 
Very low 
density 
lipoproteins 
Apo-
lipoprotein  
A-1 
Apolipoprotein 
B 
portal vein 
– Control  
 
r -0.339 
 
0.945 
 
-0.313 
 
-0.246 
 
0.971 
 
-0.159 
 
-.412 
 
-.403 
 
 P-value NS < 0.01 NS NS < 0.01 NS < 0.05 <0.05 
portal vein 
– Nephrot-
ic 
r 0.129 0.150 0.021 0.276 0.013 0.151 0.717 0.696 
 P-value NS NS NS NS NS NS < 0.05 < 0.05 
Group  Total cho-
lesterol 
Trigly 
cerides 
Phospho-
lipids 
Low 
density 
lipo-
proteins 
High 
density  
lipo-
proteins 
Very low 
density 
lipoproteins 
Apo-
lipoprotein  
A-1 
Apolipoprotein 
B 
inferior 
vena cava 
– Control 
 
r -0.334 
 
0.937 
 
-0.257 
 
-0.311 
 
0.934 
 
-0.210 
 
-0.457 -0.583 
 P-value NS < 0.01 NS NS < 0.01 NS < 0.05 <0.05 
inferior 
vena cava 
– Nephrot-
ic 
r 0.192 0.396 0.581 0.182 0.025 0.364 0.624 0.139 
 P-value NS NS < 0.05 NS NS NS < 0.05 NS 
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DISCUSSION 
Many authors have demonstrated that 
leptin is synthesized in the liver in addition 
to many other tissues including the stom-
ach, ovary, and placenta (Soukas et al., 
1999; Margetic et al., 2002).  
On the other hand, the liver, spleen, and 
kidney may participate in leptin clearance 
(Kochan et al., 2006; Zivna et al., 2002; 
Makoto et al., 2001). However, the mecha-
nism of leptin degradation/clearance has not 
been well established in humans; liver is 
proposed to be the most likely organ which 
degrades circulating leptin in vivo (Van 
Heek et al., 1996). 
In the present work, there was a non-
significant rise in leptin in the inferior vena 
cava compared with the portal venous blood 
of normal rats. Other studies supported our 
work suggesting that there was parallel syn-
thesis and clearance of leptin by liver 
(Kochan et al., 2006; Margetic et al., 2002; 
Zivna et al., 2002; Makoto et al., 2001; 
Shimizu et al., 1998). In contrast, we found 
a significant rise in leptin in the inferior ve-
na cava compared with its level in the portal 
venous blood of nephrotic rats (Table 1). 
Makoto et al. (2001) suggested that leptin is 
cleared in part by the portosystemic circula-
tion through the liver while the kidneys 
play a principal role in the elimination of 
this peptide (Henmi et al., 2008). 
Henmi et al. (2008) have confirmed in-
creased soluble leptin receptor (sOB-R) 
concentration in nephrotic patients, as com-
pared with the healthy subjects, and this 
soluble form of receptor (Ob-Re, also 
known as sOb-R), which lacks a transmem-
brane domain, is directly released into the 
circulation, whereas by binding leptin, it 
controls the amount of free leptin and the 
rate of leptin clearance (Zastrow et al. 
2003). 
Cohen et al. (2005) demonstrated that 
the liver is a major source of plasma-
soluble leptin receptor (SLR) expression in 
some states (negative energy balance) and 
indicated a novel role for the liver in modu-
lating leptin action. Thus their study re-
vealed an unexpected role of the liver in 
modulating total circulating leptin levels 
and possibly its biological activity which is 
in accordance with our findings. 
Nephrotic syndrome is accompanied by 
enlargement of the liver due to accumula-
tion of neutral fats (triglycerides) in the 
hepatocytes. Many authors have demon-
strated that serum leptin levels were also 
significantly higher in subjects with fatty 
liver and that the concentration of circulat-
ing leptin correlates with fatty liver caused 
by accumulation of visceral fat (Tobe et al., 
1999) which support our finding in their 
study. Huang et al. (2001) demonstrated 
that high levels of leptin can be caused by 
the delayed clearance of leptin from the cir-
culation due to binding to its soluble recep-
tor. The authors concluded that sOB-R is 
up-regulated and an over-expression of 
plasma-soluble leptin receptor (sOB-R) re-
sults in an increase of circulating leptin in 
nephrotic syndrome. In addition Cohen et 
al. (2005) indicated that the liver is a major 
source of plasma-soluble leptin receptor 
(SLR) expression, this illustrates the rise of 
leptin level in inferior vena cava. Moreover 
the rise in the level of leptin in the inferior 
vena cava of nephrotic rats might reflect 
decreased clearance of the hormone by the 
liver because of the fatty changes in this 
disease. 
In the present work, there was a high se-
rum leptin level in the nephrotic rats com-
pared with the normal controls (Table 1). 
However many authors demonstrated no 
significant difference in plasma leptin con-
centrations between the healthy subjects 
and nephrotic patients (Henmi et al., 2008; 
Wasilewska et al., 2005; Ozata et al., 2002; 
Tobe et al., 1999). 
But Huang et al. (2001) demonstrated 
that high levels of leptin in nephrosis can be 
caused by the delayed clearance of leptin 
from the circulation due to binding to its 
soluble receptor. They concluded that sOB-
R is up-regulated and an over-expression of 
sOB-R resulted in an increase of circulating 
leptin in nephrotic syndrome (Henmi et al., 
2008). These results are in accordance with 
the results of the present work. We add that 
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our method of induction of nephrotic syn-
drome used unilateral nephrectomized rats 
so the amount of clearance and elimination 
of leptin by one kidney is less than that by 
two kidneys. This leads to increase of leptin 
in our experimental circumstances. This 
explanation is in line with the findings of 
Toblli et al. (2002) who suggested that adri-
amycin-induced nephrotic rats had fatty liv-
ers and they demonstrated that a number of 
clinical entities, including nephrotic syn-
drome, present light to moderate enlarge-
ment of the liver due to accumulation of 
neutral fats (triglycerides) in the hepato-
cytes. Even though the outcome of hepatic 
steatosis does not seem to be harmful, when 
an additional inflammatory component is 
present, a variable degree of hepatic fibrosis 
and chronic liver disease could occur. Other 
authors demonstrated that serum leptin lev-
els were also significantly higher in subjects 
with fatty liver that the concentration of cir-
culating leptin correlates with fatty liver 
caused by accumulation of visceral fat (To-
be et al., 1999). Leptin is secreted by hepat-
ic stellate cells and it acts locally in the liv-
er and causes fibrosis (Crespo et al., 2002). 
The present finding indicated  signifi-
cant rises in the serum lipids in the inferior 
vena cava blood compared with in the por-
tal veins of nephrotic rats (Table 2). This 
excludes intestinal absorption of fats from 
being a source of increased serum lipids. 
Several workers had previously shown the 
increased hepatic apo A-I secretion in their 
nephrotic models (Medyńska et al., 2008; 
Sparks et al., 1981). 
Sparks et al. (1981) reported that the 
high levels of apo A-I in the plasma of ne-
phrotic rats was due to increased hepatic 
synthesis which resulted in an expansion of 
the pool size and saturation of the  catabolic 
pathways. They were in the opinion that 
small increases in apo A-I synthesis lead to 
large increases in its concentration in the 
plasma and saturation of catabolic path-
ways.  
Studies also showed that the relation-
ship between leptin and lipid levels in pa-
tients with chronic glomerulonephritis is 
limited (Wu and Windmueller, 2001). 
Wu and Windmueller (2001) demon-
strated a positive correlation between serum 
leptin and triglyceride and LDL levels in 
healthy children, and a negative correlation 
between serum leptin and HDL; this coor-
dinates with our finding in the control rats. 
It was suggested that there is a relationship 
between leptin concentration and certain 
markers of the metabolic syndrome, includ-
ing cholesterol, triglycerides and apolipo-
proteins (Fujimaki et al., 2001; Tamer et al., 
2002). A substantial disturbance of lipid 
metabolism occurs in children with idio-
pathic nephrotic syndrome (Delvin et al., 
2003; Vaziri, 2003). 
Haluzík et al. (2000) concluded that se-
rum leptin levels in most types of hyper-
lipidemia simply reflect the degree of adi-
posity expressed by BMI and are not clearly 
related to serum lipid and/or lipoprotein 
concentrations. Our results are in agreement 
with Wasilewska et al. (2005) who reported 
a positive correlation of leptin with total 
cholesterol, its LDL fraction and HDL frac-
tion and a negative correlation with and apo 
A and apolipoprotein B (apo B) in nephro-
tic children(Tables 3, 4). In conclusion, the 
present study suggests that the liver plays 
an important role in leptin and lipids profile 
metabolism in nephrotic rats. 
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